Stay updated on Surufatinib in Biliary Tract Carcinoma: Clinical Trial
Sign up to get notified when there's something new on the Surufatinib in Biliary Tract Carcinoma: Clinical Trial page.

Latest updates to the Surufatinib in Biliary Tract Carcinoma: Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoNo Change Detected
- Check20 days agoChange DetectedThe page revision updated from v3.2.0 to v3.3.2. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check27 days agoChange DetectedNotice about potential delays due to government funding has been removed; core trial details, contacts, and locations remain unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check42 days agoChange DetectedUpdates appear to be minor formatting and wording adjustments across sections. There are no changes to the study design, primary or secondary outcomes, enrollment numbers, or eligibility criteria.SummaryDifference0.4%

- Check71 days agoChange DetectedUpdated the page to v3.2.0 with a prominent notice about government funding impacts and NIH Clinical Center status; removed the previous v3.1.0 label.SummaryDifference3%

- Check78 days agoChange DetectedUpdate includes new revision tag v3.1.0 and new contact numbers (+86 21 20673222, +86 21 20673203), replacing the old revision tag v3.0.2.SummaryDifference0.1%

- Check92 days agoChange DetectedRevision updated from v3.0.1 to v3.0.2; 'Back to Top' was removed. Overall content remains the same aside from metadata and navigation.SummaryDifference0.2%

Stay in the know with updates to Surufatinib in Biliary Tract Carcinoma: Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Surufatinib in Biliary Tract Carcinoma: Clinical Trial page.